These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 16703262)
21. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. Lee SA; Jung M J Biol Chem; 2007 May; 282(20):15271-83. PubMed ID: 17371872 [TBL] [Abstract][Full Text] [Related]
22. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225 [TBL] [Abstract][Full Text] [Related]
24. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837 [TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775 [TBL] [Abstract][Full Text] [Related]
26. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL). Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254 [TBL] [Abstract][Full Text] [Related]
27. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
28. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Voelkel-Johnson C; King DL; Norris JS Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034 [TBL] [Abstract][Full Text] [Related]
29. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Malathi K; Paranjape JM; Ganapathi R; Silverman RH Cancer Res; 2004 Dec; 64(24):9144-51. PubMed ID: 15604285 [TBL] [Abstract][Full Text] [Related]
30. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097 [TBL] [Abstract][Full Text] [Related]
31. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Nakshatri H; Rice SE; Bhat-Nakshatri P Oncogene; 2004 Sep; 23(44):7330-44. PubMed ID: 15286701 [TBL] [Abstract][Full Text] [Related]
32. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Sinicrope FA; Penington RC Mol Cancer Ther; 2005 Oct; 4(10):1475-83. PubMed ID: 16227396 [TBL] [Abstract][Full Text] [Related]
33. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]
34. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I; Marciniak RA Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201 [TBL] [Abstract][Full Text] [Related]
35. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Weldon CB; Parker AP; Patten D; Elliott S; Tang Y; Frigo DE; Dugan CM; Coakley EL; Butler NN; Clayton JL; Alam J; Curiel TJ; Beckman BS; Jaffe BM; Burow ME Int J Oncol; 2004 Jun; 24(6):1473-80. PubMed ID: 15138590 [TBL] [Abstract][Full Text] [Related]
36. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Kandasamy K; Srivastava RK Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743 [TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472 [TBL] [Abstract][Full Text] [Related]
38. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Bockbrader KM; Tan M; Sun Y Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155 [TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Gibson EM; Henson ES; Haney N; Villanueva J; Gibson SB Cancer Res; 2002 Jan; 62(2):488-96. PubMed ID: 11809700 [TBL] [Abstract][Full Text] [Related]
40. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]